Loading...

Watch and Wait or Continuous Therapy for Follicular Lymphoma: Where Are We Now?

1,331 views

Loading...

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 22, 2014

Newly approved medications are beginning to offer patients with indolent lymphomas new options for continuous disease control, while avoiding some of the side effects of traditional chemotherapy treatments. The question for many patients is whether or not these drugs might extend their lives longer than the traditional approach of watching and waiting to disease progression and treating only after the tumor has gotten larger. Dr. Wyndham Wilson from the National Cancer Institute joins Dr. John Gribben from Barts Cancer Center in London at the 2014 International Workshop on Non-Hodgkin Lymphoma to discuss these issues and their perspective for patients today.

Read the transcript | http://www.patientpower.info/video/ho...

Dr. Wilson is the head of lymphoma therapeutics at the National Cancer Institute.

View more programs with Dr. Wilson | http://www.patientpower.info/bio/wynd...

Dr. Gribben is an internationally recognized translational cancer researcher at the Barts Cancer Center in London.

View more programs with Dr. Gribben | http://www.patientpower.info/bio/john...

Get email alerts | http://www.patientpower.info/lymphoma...

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo

  • Category

  • License

    • Standard YouTube License

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...